Katherine Margaret Berg

Katherine Margaret Berg

Auto-generated profile, based on publicly available information

Katherine Margaret Berg

Center for Resuscitation Science, Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Resuscitation
Verified
Journal Article
Closed access
LWLise Witten
Lise Witten
RGRyan Gardner
Ryan Gardner
MHMathias J. Holmberg
Mathias J. Holmberg
SWSebastian Wiberg
Sebastian Wiberg
AMAri Moskowitz
Ari Moskowitz
KBKatherine M. Berg
Katherine M. Berg

29 October 2018 in Critical Care
Verified
Journal Article
Open access
PDF file
AMAri Moskowitz
Ari Moskowitz
LALars W. Andersen
Lars W. Andersen
DHDavid T. Huang
David T. Huang
KBKatherine M. Berg
Katherine M. Berg
NMNeeharika Munjal
Neeharika Munjal
MDMichael W. Donnino
Michael W. Donnino
The combination of thiamine, ascorbic acid, and hydrocortisone has recently emerged as a potential adjunctive therapy to antibiotics, infectious source control, and supportive care for patients with sepsis and septic shock. In the present manuscript, we provide a comprehensive review of the pathophysiologic basis and supporting research for each element of the thiamine, ascorbic acid, and hydrocortisone drug combination in sepsis. In addition, we describe potential areas of synergy between these therapies and discuss the strengths/weaknesses of the two studies to date which have evaluated the drug combination in patients with severe infection. Finally, we describe the current state of current clinical practice as it relates to the thiamine, ascorbic acid, and hydrocortisone combination and present an overview of the randomized, placebo-controlled, multi-center Ascorbic acid, Corticosteroids, and Thiamine in Sepsis (ACTS) trial and other planned/ongoing randomized clinical trials.

1 June 2020 in Resuscitation
Verified
Journal Article
Closed access
GPG.D. Perkins
G.D. Perkins
PMP.T. Morley
P.T. Morley
JNJ.P. Nolan
J.P. Nolan
JSJ. Soar
J. Soar
KBK. Berg
K. Berg
RNR. Neumar
R. Neumar

1 June 2019 in Resuscitation
Verified
Journal Article
Closed access
MHMathias J. Holmberg
Mathias J. Holmberg
MIMahmoud S. Issa
Mahmoud S. Issa
AMAri Moskowitz
Ari Moskowitz
PMPeter Morley
Peter Morley
MWMichelle Welsford
Michelle Welsford
TWTzong-Luen Wang
Tzong-Luen Wang

1 July 2020 in Resuscitation
Verified
Journal Article
Closed access
MHMathias J. Holmberg
Mathias J. Holmberg
TNTonia Nicholson
Tonia Nicholson
JNJerry P. Nolan
Jerry P. Nolan
SSSteve Schexnayder
Steve Schexnayder
JRJoshua Reynolds
Joshua Reynolds
KBKatherine M. Berg
Katherine M. Berg

3 April 2016 in Critical Care
Verified
Journal Article
Open access
PDF file
TGthe collaborating authors from the Beth Israel Deaconess Medical Center’s Center for Resuscitation Science Research Group
the collaborating authors from the Beth Israel Deaconess Medical Center’s Center for Resuscitation Science Research Group
MDMichael W. Donnino
Michael W. Donnino
LALars W. Andersen
Lars W. Andersen
KBKatherine M. Berg
Katherine M. Berg
MCMaureen Chase
Maureen Chase
MCMichael N. Cocchi
Michael N. Cocchi
The purpose of this study was to determine whether the provision of corticosteroids improves time to shock reversal and outcomes in patients with post-cardiac arrest shock. We conducted a randomized, double-blind trial of post-cardiac arrest patients in shock, defined as vasopressor support for a minimum of 1 hour. Patients were randomized to intravenous hydrocortisone 100 mg or placebo every 8 hours for 7 days or until shock reversal. The primary endpoint was time to shock reversal. Fifty patients were included with 25 in each group. There was no difference in time to shock reversal between groups (hazard ratio: 0.83 [95 % CI: 0.40–1.75], p = 0.63). We found no difference in secondary outcomes including shock reversal (52 % vs. 60 %, p = 0.57), good neurological outcome (24 % vs. 32 %, p = 0.53) or survival to discharge (28 % vs. 36 %, p = 0.54) between the hydrocortisone and placebo groups. Of the patients with a baseline cortisol < 15 ug/dL, 100 % (6/6) in the hydrocortisone group achieved shock reversal compared to 33 % (1/3) in the placebo group (p = 0.08). All patients in the placebo group died (100 %; 3/3) whereas 50 % (3/6) died in the hydrocortisone group (p = 0.43). In a population of cardiac arrest patients with vasopressor-dependent shock, treatment with hydrocortisone did not improve time to shock reversal, rate of shock reversal, or clinical outcomes when compared to placebo. Clinicaltrials.gov: NCT00676585 , registration date: May 9, 2008.